137102-65-9

Basic information

• Product Name: [(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER
• Synonyms: tert-butyl (R)-(2-amino-1-phenylethyl)carbamate;[(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER;(R)-2-(Boc-aMino)-2-phenylethylaMine
• CAS NO: 137102-65-9
• Molecular Formula: C₁₃H₂₀N₂O₂
• Molecular Weight: 236.313
• Mol File: 137102-65-9.mol

Chemical Properties

• Boiling Point: 372.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.066±0.06 g/cm3(Predicted)
• PKA: 11?+-.0.46(Predicted)
• CAS DataBase Reference: [(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER(137102-65-9)
• EPA Substance Registry System: [(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER(137102-65-9)

Safety Data

• Hazardous Substances Data: 137102-65-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is used as a therapeutic agent for the treatment of neurological disorders due to its potential to alleviate symptoms and improve patient outcomes.
Used in Chemical Research and Development:
[(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is used as a reagent in chemical reactions to form new compounds with potential pharmaceutical or industrial uses, contributing to the advancement of scientific knowledge and the creation of novel products.
Used in Drug Synthesis:
[(1R)-2-AMINO-1-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is utilized as a key component in the synthesis of various drugs, particularly those targeting neurological conditions, due to its unique chemical properties and reactivity.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 312532-36-8 {(R)-2-[2-((S)-1-Hydroxy-2,2-dimethyl-propyl)-4-oxo-4H-quinazolin-3-ylamino]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 134557-76-9 (R)-(-)-1-<(butoxycarbonyl)amino>-1-phenylethyl azide 
• 221352-64-3 dicyclohexylammonium (R)-2-((tert-butoxycarbonyl)amino)pent-4-enoate 
• 102-96-5 (2-nitroethenyl)benzene 
• 79722-21-7 tert-butyl N-(benzyloxy)carbamate 
• 1312926-11-6 tert-butyl benzyloxy(2-nitro-1-phenylethyl)carbamate 
• 201730-82-7 3-((R)-2-Azido-2-phenyl-ethylamino)-2-((S)-1-hydroxy-2,2-dimethyl-propyl)-3H-quinazolin-4-one 
• 201730-83-8 3-((R)-2-Chloro-2-phenyl-ethylamino)-2-((S)-1-hydroxy-2,2-dimethyl-propyl)-3H-quinazolin-4-one 
• 177896-09-2 tert-butyl benzylidenecarbamate 
• 155396-71-7 tert-butyl N-(phenyl(phenylsulfonyl)methyl)carbamate 
• 150884-50-7 benzaldehyde N-boc imine 
• 100-52-7 benzaldehyde 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 1172596-82-5 tert-butyl (R)-2-isothiocyanato-1-phenylethylcarbamate 
• 914649-54-0 Pyridine-2-carboxylic acid ((R)-2-amino-2-phenyl-ethyl)-amide 

Relevant articles and documents

Preparation method of key intermediate of elagolix

The invention relates to the field of pharmacy, and concretely relates to a preparation method of a key intermediate of elagolix. The method adopts simple and easily available Boc-D-phenylglycinol asa starting material, and comprises the following steps:

Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity

In the preceding manuscript [Moreau et al. 2018, 10.1021/acs.jmedchem.7b01691] we described a successful fragment-based lead discovery (FBLD) strategy for discovery of bacterial phosphopantetheine adenylyltransferase inhibitors (PPAT, CoaD). Following several rounds of optimization two promising lead compounds were identified: triazolopyrimidinone 3 and 4-azabenzimidazole 4. Here we disclose our efforts to further optimize these two leads for on-target potency and Gram-negative cellular activity. Enabled by a robust X-ray crystallography system, our structure-based inhibitor design approach delivered compounds with biochemical potencies 4-5 orders of magnitude greater than their respective fragment starting points. Additional optimization was guided by observations on bacterial permeability and physicochemical properties, which ultimately led to the identification of PPAT inhibitors with cellular activity against wild-type E. coli.

SYNTHESIS OF ARYL CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS

Synthesis methods to produce a series of carboxamides built off of an (S)-2-amino acid backbone or an (R)-2-amino acid backbone, depending upon the desired diastereomer of the end product.

SONIC HEDGEHOG MODULATORS

Sonic Hedgehog modulators and methods of use thereof are provided for.

Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: Potent inhibitors of R5 HIV-1 replication

The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure-activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (R5) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.

Asymmetric neutral amination of nitroolefins catalyzed by chiral bifunctional ammonium salts in water-rich biphasic solvent

It′s just a phase: Environmentally benign title reaction was achieved under neutral phase-transfer conditions in the presence of 0.05 mol% of a chiral bifunctional ammonium bromide. The importance of bifunctional design of the chiral phase-transfer catalysts (PTC) was clearly shown in the transition-state model of the reaction based on the single-crystal X-ray structure. Bn=benzyl, Boc=tert-butoxycarbonyl.

N-urethane-protected amino alkyl isothiocyanates: Synthesis, isolation, characterization, and application to the synthesis of thioureidopeptides

(Chemical Equation Presented) Synthetically useful N-Fmoc amino-alkyl isothiocyanates have been described, starting from protected amino acids. These compounds have been synthesized in excellent yields by thiocarbonylation of the monoprotected 1,2-diamines with CS2/TEA/p-TsCl, isolated as stable solids, and completely characterized. The procedure has been extended to the synthesis of amino alkyl isothiocyanates from Boc- and Z-protected amino acids as well. The utility of these isothiocyanates for peptidomimetics synthesis has been demonstrated by employing them in the preparation of a series of dithioureidopeptide esters. Boc-Gly-OH and Boc-Phe-OH derived isothiocyanates 9a and 9c have been obtained as single crystals and their structures solved through X-ray diffraction. They belong to the orthorhombic crystal system, and have a single molecule in the asymmetric unit (Z′ = 1). 9a crystallizes in the centrosymmetric space group Pbca, while 9c crystallizes in the noncentrosymmetric space group P212121.

Asymmetric hydrogenation of aromatic ketones catalyzed by the TolBINAP/DMAPEN-ruthenium(II) complex: A significant effect of N-substituents of chiral 1,2-diamine ligands on enantioselectivity

(Chemical Equation Presented) Asymmetric hydrogenation of acetophenone in the presence of Ru(II) catalysts coordinated by TolBINAP and a series of chiral 1,2-diamines was studied. The sense and degree of enantioselectivity were highly dependent on the N-substituents of the diamine ligands. The N-substituent effect was discussed in detail. Among these catalysts, the (S)-TolBINAP/(R)- DMAPEN-Ru(II) complex showed the highest enantioselectivity. The mode of enantioface selection was interpreted by using transition state models based on the X-ray structure of the catalyst precursor. The chiral catalyst effected the hydrogenation of alkyl aryl ketones and arylglyoxal dialkyl acetals to afford the chiral alcohol in >99% ee in the best cases. Hydrogenation of racemic benzoin methyl ether with the chiral catalyst through dynamic kinetic resolution gave the anti-alcohol (syn:anti = 3:97) in 98% ee, while the reaction of α-amidopropiophenones resulted in the syn-alcohols (symanti = 96:4 to >99:1) in >98% ee.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Bifunctional-thiourea-catalyzed diastereo- And enantioselective Aza-Henry reaction

Bifunctional thiourea 1a catalyzes aza-Henry reaction of nitroalkanes with N-Boc-imines to give syn-β-nitroamines with good to high diastereo- and enantioselectivity. Apart from the catalyst, the reaction requires no additional reagents such as a Lewis acid or a Lewis base. The N-protecting groups of the imines have a determining effect on the chirality of the prod ucts, that is, the reaction of N-Bocimines gives R adducts as major products, whereas the same reaction of N-phosphonoylimines furnishes the corresponding S adducts. Various types of nitroalkanes bearing aryl, alcohol, ether, and ester groups can be used as nucleophiles, providing access to a wide range of useful chiral building blocks in good yield and high enantiomeric excess. Synthetic versatility of the addition products is demonstrated by the transformation to chiral piperidine derivatives such as CP-99,994.